Journal of Clinical & Biomedical Research

Interleukin-11 (IL-11) is a member of the IL-6 family of cytokines and has garnered attention for its multifaceted roles in various biological processes, particularly in the context of aging and lifespan modulation. This cytokine is implicated in several pathophysiological conditions, including inflammation, fibrosis, and cancer, and its expression levels have been associated with aging-related changes in immune function and tissue homeostasis. Understanding the role of IL-11 in aging and lifespan is crucial, as it may provide insights into potential therapeutic interventions to promote healthy aging and longevity. IL-11 is known to exert pleiotropic effects through its interaction with the gp130 receptor complex, leading to the activation of the STAT3 signaling pathway. This pathway is critical for mediating the biological effects of IL-11, including its role in promoting inflammation and fibrosis [1,2]. In the context of aging, elevated levels of pro- inflammatory cytokines, including IL-11, have been linked to increased morbidity and mortality in elderly populations [3]. The chronic low-grade inflammation observed in aging is characterized by heightened levels of various cytokines, including IL-6 and IL-11, which may contribute to the decline in immune function and the increased risk of age-related diseases [4,5]. Research has demonstrated that IL-11 plays a significant role in regulating bone metabolism, influencing the differentiation and activity of osteoclasts and osteoblasts [6]. This is particularly relevant in aging, as bone density and strength decline, leading to conditions such as osteoporosis. IL-11’s involvement in bone metabolism may be critical in maintaining skeletal health during aging.

Furthermore, studies have shown that IL-11 can promote osteolysis in cancer metastasis, indicating its dual role in both normal physiological processes and pathological conditions [6]. In addition to its effects on bone metabolism, IL-11 has been implicated in regulating cardiac health. Elevated IL-11 levels have been associated with cardiac fibrosis, a condition that can lead to heart failure, particularly in older adults [7]. The profibrotic effects of IL-11 are mediated through its ability to enhance the activation of fibroblasts and promote extracellular matrix deposition, which can disrupt normal cardiac function [8]. This highlights the potential of targeting IL-11 signaling pathways as a therapeutic strategy to mitigate age-related cardiac dysfunction.

Moreover, IL-11’s role in the immune system is noteworthy, as it influences the polarization of T helper cells, particularly Th17 cells, which are involved in inflammatory responses [9]. The dysregulation of immune responses mediated by IL- 11 may contribute to the increased susceptibility to infections and autoimmune diseases observed in aging populations. The interplay between IL-11 and other cytokines, such as IL-6, further complicates its role in immune regulation during aging [10]. Studies have indicated that neutralizing IL-11 can improve renal function and increase lifespan in mouse models of Alport syndrome, a genetic disorder characterized by progressive kidney failure [11]. This finding underscores the potential of IL-11 as a therapeutic target in age-related kidney diseases, suggesting that modulating its activity could benefit longevity and overall health span.

Furthermore, the protective roles of IL-11 in various organ systems, including the liver and lungs, have been documented. IL-11 has been shown to attenuate liver ischemia/reperfusion injury and to play a protective role in models of non-alcoholic fatty liver disease [12,13]. IL-11 is implicated in the pathogenesis of idiopathic pulmonary fibrosis in the lungs, where its expression is significantly elevated [14]. These findings suggest that IL-11 may have a complex role in organ-specific responses to injury and inflammation, which could be influenced by aging. The potential of IL-11 as a biomarker for aging and age-related diseases is also an area of active research. Elevated levels of IL-11 have been associated with various cancers, indicating its role in tumorigenesis and disease progression [15,16]. The correlation between IL- 11 levels and cancer prognosis further emphasizes the need for understanding its role in aging, as cancer risk increases with age.

In conclusion, IL-11 is a multifaceted cytokine that plays significant roles in aging and lifespan regulation. Its involvement in inflammation, fibrosis, immune modulation, and organ health highlights its potential as a therapeutic target for promoting healthy aging and longevity. The potential of IL-11 as a biomarker for age-related diseases, a promising area of active research, should pique the audience’s curiosity about its future applications. Future research should focus on elucidating the precise mechanisms by which IL-11 influences aging processes and exploring its potential as a biomarker for age-related diseases.

References

1. Putoczki TL, Dobson RCJ, Griffin MDW (2014) The structure of human interleukin-11 reveals receptor-binding site features and structural differences from interleukin-6. Acta Crystallographic Section D Biological Crystallography 70: 2277-2285.
2. Wu J, Ma W, Qiu Z, Zhou Z (2023) Roles and mechanism of il-11 in vascular diseases. Frontiers in Cardiovascular Medicine 10: 3389-3387.
3. Yarbro JW, Pence BD (2018) Monocytes in aging and exercise. Exercise Medicine 2: 15-20.
4. Puzianowska-Ku?nicka M, Owczarz M, Wieczorowska- Tobis K, Nadrowski P, Chudek J, et (2016) Interleukin-6 and c-reactive protein, successful aging, and mortality: the polsenior study. Immunity &Amp Ageing 13: 21.
5. Han Y, Gao H, Gan, X, Liu J, Bao C, et al. (2024) Roles of il-11 in the regulation of bone metabolism. Frontiers in Endocrinology 14: 1290130.
6. Liang M, Ma Q, Ding N, Luo F, Bai Y, et al. (2019) Il-11 is essential in promoting osteolysis in breast cancer bone metastasis via rank-independent activation of osteoclast genesis. Cell Death &Amp Disease 10: 353.
7. Schäfer S, Sivakumar V, Widjaja AA, Lim W, Moreno-Moral A, et (2017) Il-11 is a crucial determinant of cardiovascular fibrosis. Nature 552: 110-115.
8. Wu J, Ma W, Qiu Z, Zhou Z (2023) Roles and mechanism of il-11 in vascular diseases. Frontiers in Cardiovascular Medicine 10: 1171697.
9. Zhang X, Tao Y, Chopra M, Dujmovic-Basuroski I, Jin J, et al. (2015) Il-11 induces th47 cell responses in patients with early relapsing-remitting multiple sclerosis. J Immunol 19: 5139-5149.
10. Zou R, Huang X, Xu P (2021) The study of gp130/the inflammatory factors regulating osteoclast differentiation in rheumatoid arthritis. Biochem Biophys Reports 26: 10934-
11. Widjaja AA, Shekeran SG, Adami E, Goh JWT, Tan J, et (2022) A neutralizing il-11 antibody improves renal function and increases lifespan in a mouse model of Alport syndrome. J of the Am Soc Nephrology 33: 718-730.
12. Zhu M, Lü B, Cao Q, Wu ZXZ, L Liu F (2015) Il-11 attenuates liver ischemia/reperfusion injury through stat3 signaling pathway in mice. Plos One 10: e0126296.
13. Widjaja AA, Singh BK, Adami E, Sivakumar V, Dong J, et (2019) Inhibiting interleukin 11 signaling reduces hepatocyte death and liver fibrosis, inflammation, and steatosis in mouse models of nonalcoholic steatohepatitis. Gastroenterology 157: 777-792.
14. Ng B, Dong J, D’Agostino G, Sivakumar V, Widjaja AA, et al. (2019) Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis. Sci Transl Med 11: 511.
15. Putoczki TL, Thiem S, Loving A, Busuttil RA, Wilson NJ, et al. (2013) Interleukin-11 is the dominant il-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 24: 257-271.
16. Wu D, Tao J, Ding J, Qü P, Lü Q, et (2012) Interleukin-11, an interleukin-6-like cytokine, is a promising predictor for bladder cancer prognosis. Mol Med Reports 7: 684-ss688